Rights & Society
EMA Restricts Use of Tecovirimat SIGA
The European Medicines Agency's (EMA) Committee for Human Medicines (CHMP) has recommended restricting the use of Tecovirimat SIGA, an antiviral medication, for the treatment of mpox (formerly known as monkeypox). The CHMP recommendation specifies that Tecovirimat SIGA should no longer be used to treat mpox. This decision is based on a reassessment of the available data and evidence. The recommendation does not impact the use of the drug for other approved indications.
EMA advises against using Tecovirimat SIGA for mpox treatment.